celltrace violet cell proliferation kit, for flow cytometry Search Results


dual luciferase firefly renilla assay system  (BPS Bioscience)
94
BPS Bioscience dual luciferase firefly renilla assay system
Dual Luciferase Firefly Renilla Assay System, supplied by BPS Bioscience, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/celltrace+violet+cell+proliferation+kit%2C+for+flow+cytometry/Dual+Luciferase+(Firefly-Renilla)+Assay+System/pmc09501368-56-22-27
Average 94 stars, based on 1 article reviews
dual luciferase firefly renilla assay system - by Bioz Stars, 2026-09
94/100 stars
  Buy from Supplier
celltrace violet cell proliferation kit  (Thermo Fisher)
99
Thermo Fisher celltrace violet cell proliferation kit
Celltrace Violet Cell Proliferation Kit, supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/celltrace+violet+cell+proliferation+kit%2C+for+flow+cytometry/PBS/pm36761778-99-5-10
Average 99 stars, based on 1 article reviews
celltrace violet cell proliferation kit - by Bioz Stars, 2026-09
99/100 stars
  Buy from Supplier
celltrace cfse  (Thermo Fisher)
97
Thermo Fisher celltrace cfse
Frequency and characteristics of Treg subsets in patients with HNSCC and in those with benign tumors. The gating strategies for Treg subsets in the PBMCs of patients with HNSCC or benign tumors. I: CD45RA+Foxp3low, II: CD45RA−Foxp3low, and III: CD45RA−Foxp3high (a). The expression of CTLA-4, CD25, and CCR4 on Treg subsets in a representative patient with HNSCC (b). Mean fluorescence intensities (MFI) are indicated in the upper right quadrant. <t>CFSE</t> dilutions of proliferated CD4+ T cells were assessed after 72 h of TCR stimulation with or without indicated Treg subsets at a 1:1 ratio (c), and the number of proliferated CD4+ T cells after the co-culture are shown (d). The percentage of Foxp3+ cells in CD4+ T cells (e), CD45RA−Foxp3high Tregs in CD4+ T cells (F), CD45RA+Foxp3low Tregs in CD4+ T cells (g) and the ratio of CD45RA−Foxp3high Tregs to CD45RA+Foxp3low Tregs (h) in PBMCs of patients with HNSCC (n = 46) and benign tumors (n = 23) before treatment. The percentage of CD45RA−Foxp3high Tregs and the ratio of CD45RA−Foxp3high Tregs to CD45RA+Foxp3low Tregs were increased according to clinical stage (i). Statistical comparisons were performed using the parametric unpaired t test. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001. n.s. not significant, HNSCC head and neck squamous cell carcinoma, CTLA-4 cytotoxic T-lymphocyte antigen 4, CCR CC chemokine receptor, CFSE carboxyfluorescein diacetate succinimidyl ester, TCR T cell receptor
Celltrace Cfse, supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/celltrace+violet+cell+proliferation+kit%2C+for+flow+cytometry/5(6)-Carboxyfluorescein/pmc11029772-128-8-17
Average 97 stars, based on 1 article reviews
celltrace cfse - by Bioz Stars, 2026-09
97/100 stars
  Buy from Supplier
celltracks vr autoprep vr system  (CellSearch inc)
90
CellSearch inc celltracks vr autoprep vr system
Frequency and characteristics of Treg subsets in patients with HNSCC and in those with benign tumors. The gating strategies for Treg subsets in the PBMCs of patients with HNSCC or benign tumors. I: CD45RA+Foxp3low, II: CD45RA−Foxp3low, and III: CD45RA−Foxp3high (a). The expression of CTLA-4, CD25, and CCR4 on Treg subsets in a representative patient with HNSCC (b). Mean fluorescence intensities (MFI) are indicated in the upper right quadrant. <t>CFSE</t> dilutions of proliferated CD4+ T cells were assessed after 72 h of TCR stimulation with or without indicated Treg subsets at a 1:1 ratio (c), and the number of proliferated CD4+ T cells after the co-culture are shown (d). The percentage of Foxp3+ cells in CD4+ T cells (e), CD45RA−Foxp3high Tregs in CD4+ T cells (F), CD45RA+Foxp3low Tregs in CD4+ T cells (g) and the ratio of CD45RA−Foxp3high Tregs to CD45RA+Foxp3low Tregs (h) in PBMCs of patients with HNSCC (n = 46) and benign tumors (n = 23) before treatment. The percentage of CD45RA−Foxp3high Tregs and the ratio of CD45RA−Foxp3high Tregs to CD45RA+Foxp3low Tregs were increased according to clinical stage (i). Statistical comparisons were performed using the parametric unpaired t test. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001. n.s. not significant, HNSCC head and neck squamous cell carcinoma, CTLA-4 cytotoxic T-lymphocyte antigen 4, CCR CC chemokine receptor, CFSE carboxyfluorescein diacetate succinimidyl ester, TCR T cell receptor
Celltracks Vr Autoprep Vr System, supplied by CellSearch inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/celltrace+violet+cell+proliferation+kit%2C+for+flow+cytometry/celltracks+autoprep+system/pm21337491-40-14-19
Average 90 stars, based on 1 article reviews
celltracks vr autoprep vr system - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier
violet fluorescent cell barcoding kit  (Becton Dickinson)
90
Becton Dickinson violet fluorescent cell barcoding kit
Frequency and characteristics of Treg subsets in patients with HNSCC and in those with benign tumors. The gating strategies for Treg subsets in the PBMCs of patients with HNSCC or benign tumors. I: CD45RA+Foxp3low, II: CD45RA−Foxp3low, and III: CD45RA−Foxp3high (a). The expression of CTLA-4, CD25, and CCR4 on Treg subsets in a representative patient with HNSCC (b). Mean fluorescence intensities (MFI) are indicated in the upper right quadrant. <t>CFSE</t> dilutions of proliferated CD4+ T cells were assessed after 72 h of TCR stimulation with or without indicated Treg subsets at a 1:1 ratio (c), and the number of proliferated CD4+ T cells after the co-culture are shown (d). The percentage of Foxp3+ cells in CD4+ T cells (e), CD45RA−Foxp3high Tregs in CD4+ T cells (F), CD45RA+Foxp3low Tregs in CD4+ T cells (g) and the ratio of CD45RA−Foxp3high Tregs to CD45RA+Foxp3low Tregs (h) in PBMCs of patients with HNSCC (n = 46) and benign tumors (n = 23) before treatment. The percentage of CD45RA−Foxp3high Tregs and the ratio of CD45RA−Foxp3high Tregs to CD45RA+Foxp3low Tregs were increased according to clinical stage (i). Statistical comparisons were performed using the parametric unpaired t test. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001. n.s. not significant, HNSCC head and neck squamous cell carcinoma, CTLA-4 cytotoxic T-lymphocyte antigen 4, CCR CC chemokine receptor, CFSE carboxyfluorescein diacetate succinimidyl ester, TCR T cell receptor
Violet Fluorescent Cell Barcoding Kit, supplied by Becton Dickinson, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/celltrace+violet+cell+proliferation+kit%2C+for+flow+cytometry/violet+fluorescent+cell+barcoding+kit/pmc04975524-46-7-12
Average 90 stars, based on 1 article reviews
violet fluorescent cell barcoding kit - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier
ghost dye violet 510 dead cell stain kit  (Cytek Biosciences)
96
Cytek Biosciences ghost dye violet 510 dead cell stain kit
Frequency and characteristics of Treg subsets in patients with HNSCC and in those with benign tumors. The gating strategies for Treg subsets in the PBMCs of patients with HNSCC or benign tumors. I: CD45RA+Foxp3low, II: CD45RA−Foxp3low, and III: CD45RA−Foxp3high (a). The expression of CTLA-4, CD25, and CCR4 on Treg subsets in a representative patient with HNSCC (b). Mean fluorescence intensities (MFI) are indicated in the upper right quadrant. <t>CFSE</t> dilutions of proliferated CD4+ T cells were assessed after 72 h of TCR stimulation with or without indicated Treg subsets at a 1:1 ratio (c), and the number of proliferated CD4+ T cells after the co-culture are shown (d). The percentage of Foxp3+ cells in CD4+ T cells (e), CD45RA−Foxp3high Tregs in CD4+ T cells (F), CD45RA+Foxp3low Tregs in CD4+ T cells (g) and the ratio of CD45RA−Foxp3high Tregs to CD45RA+Foxp3low Tregs (h) in PBMCs of patients with HNSCC (n = 46) and benign tumors (n = 23) before treatment. The percentage of CD45RA−Foxp3high Tregs and the ratio of CD45RA−Foxp3high Tregs to CD45RA+Foxp3low Tregs were increased according to clinical stage (i). Statistical comparisons were performed using the parametric unpaired t test. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001. n.s. not significant, HNSCC head and neck squamous cell carcinoma, CTLA-4 cytotoxic T-lymphocyte antigen 4, CCR CC chemokine receptor, CFSE carboxyfluorescein diacetate succinimidyl ester, TCR T cell receptor
Ghost Dye Violet 510 Dead Cell Stain Kit, supplied by Cytek Biosciences, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/celltrace+violet+cell+proliferation+kit%2C+for+flow+cytometry/Ghost+Dye+Violet+510/pm34433873-246-5-13
Average 96 stars, based on 1 article reviews
ghost dye violet 510 dead cell stain kit - by Bioz Stars, 2026-09
96/100 stars
  Buy from Supplier
celltracks analyzer  (CellSearch inc)
90
CellSearch inc celltracks analyzer
Frequency and characteristics of Treg subsets in patients with HNSCC and in those with benign tumors. The gating strategies for Treg subsets in the PBMCs of patients with HNSCC or benign tumors. I: CD45RA+Foxp3low, II: CD45RA−Foxp3low, and III: CD45RA−Foxp3high (a). The expression of CTLA-4, CD25, and CCR4 on Treg subsets in a representative patient with HNSCC (b). Mean fluorescence intensities (MFI) are indicated in the upper right quadrant. <t>CFSE</t> dilutions of proliferated CD4+ T cells were assessed after 72 h of TCR stimulation with or without indicated Treg subsets at a 1:1 ratio (c), and the number of proliferated CD4+ T cells after the co-culture are shown (d). The percentage of Foxp3+ cells in CD4+ T cells (e), CD45RA−Foxp3high Tregs in CD4+ T cells (F), CD45RA+Foxp3low Tregs in CD4+ T cells (g) and the ratio of CD45RA−Foxp3high Tregs to CD45RA+Foxp3low Tregs (h) in PBMCs of patients with HNSCC (n = 46) and benign tumors (n = 23) before treatment. The percentage of CD45RA−Foxp3high Tregs and the ratio of CD45RA−Foxp3high Tregs to CD45RA+Foxp3low Tregs were increased according to clinical stage (i). Statistical comparisons were performed using the parametric unpaired t test. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001. n.s. not significant, HNSCC head and neck squamous cell carcinoma, CTLA-4 cytotoxic T-lymphocyte antigen 4, CCR CC chemokine receptor, CFSE carboxyfluorescein diacetate succinimidyl ester, TCR T cell receptor
Celltracks Analyzer, supplied by CellSearch inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/celltrace+violet+cell+proliferation+kit%2C+for+flow+cytometry/celltracks+analyzer+ii/pm25471333-38-16-11
Average 90 stars, based on 1 article reviews
celltracks analyzer - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier
rat anti-mouse cd117-bv421 (c-kit) 2b8  (Becton Dickinson)
90
Becton Dickinson rat anti-mouse cd117-bv421 (c-kit) 2b8

Rat Anti Mouse Cd117 Bv421 (C Kit) 2b8, supplied by Becton Dickinson, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/celltrace+violet+cell+proliferation+kit%2C+for+flow+cytometry/anti+cd117/pmc07225750-3-0-7
Average 90 stars, based on 1 article reviews
rat anti-mouse cd117-bv421 (c-kit) 2b8 - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier
cfse stock solution celltrace cfse cell proliferation kit  (Thermo Fisher)
99
Thermo Fisher cfse stock solution celltrace cfse cell proliferation kit

Cfse Stock Solution Celltrace Cfse Cell Proliferation Kit, supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/celltrace+violet+cell+proliferation+kit%2C+for+flow+cytometry/Fluorescein/pmc02936966-97-4-12
Average 99 stars, based on 1 article reviews
cfse stock solution celltrace cfse cell proliferation kit - by Bioz Stars, 2026-09
99/100 stars
  Buy from Supplier
matrigel  (Corning Life Sciences)
90
Corning Life Sciences matrigel

Matrigel, supplied by Corning Life Sciences, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/celltrace+violet+cell+proliferation+kit%2C+for+flow+cytometry/matrigel/pmc09245005__mmc3-238-188-222
Average 90 stars, based on 1 article reviews
matrigel - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier
firefly & renilla dual luciferase assay kit  (Yuheng Pharmaceutical Co)
90
Yuheng Pharmaceutical Co firefly & renilla dual luciferase assay kit

Firefly & Renilla Dual Luciferase Assay Kit, supplied by Yuheng Pharmaceutical Co, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/celltrace+violet+cell+proliferation+kit%2C+for+flow+cytometry/firefly+++renilla+dual+luciferase+assay+kit/pmc10687138-96-13-21
Average 90 stars, based on 1 article reviews
firefly & renilla dual luciferase assay kit - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier
e6150s celltrace cfse cell proliferation kit  (New England Biolabs)
99
New England Biolabs e6150s celltrace cfse cell proliferation kit

E6150s Celltrace Cfse Cell Proliferation Kit, supplied by New England Biolabs, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/celltrace+violet+cell+proliferation+kit%2C+for+flow+cytometry/NEBNext+Magnesium+RNA+Fragmentation+Module/pmc06428223__NIHMS1523290___supplement___2-243-41-39
Average 99 stars, based on 1 article reviews
e6150s celltrace cfse cell proliferation kit - by Bioz Stars, 2026-09
99/100 stars
  Buy from Supplier

Image Search Results


Frequency and characteristics of Treg subsets in patients with HNSCC and in those with benign tumors. The gating strategies for Treg subsets in the PBMCs of patients with HNSCC or benign tumors. I: CD45RA+Foxp3low, II: CD45RA−Foxp3low, and III: CD45RA−Foxp3high (a). The expression of CTLA-4, CD25, and CCR4 on Treg subsets in a representative patient with HNSCC (b). Mean fluorescence intensities (MFI) are indicated in the upper right quadrant. CFSE dilutions of proliferated CD4+ T cells were assessed after 72 h of TCR stimulation with or without indicated Treg subsets at a 1:1 ratio (c), and the number of proliferated CD4+ T cells after the co-culture are shown (d). The percentage of Foxp3+ cells in CD4+ T cells (e), CD45RA−Foxp3high Tregs in CD4+ T cells (F), CD45RA+Foxp3low Tregs in CD4+ T cells (g) and the ratio of CD45RA−Foxp3high Tregs to CD45RA+Foxp3low Tregs (h) in PBMCs of patients with HNSCC (n = 46) and benign tumors (n = 23) before treatment. The percentage of CD45RA−Foxp3high Tregs and the ratio of CD45RA−Foxp3high Tregs to CD45RA+Foxp3low Tregs were increased according to clinical stage (i). Statistical comparisons were performed using the parametric unpaired t test. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001. n.s. not significant, HNSCC head and neck squamous cell carcinoma, CTLA-4 cytotoxic T-lymphocyte antigen 4, CCR CC chemokine receptor, CFSE carboxyfluorescein diacetate succinimidyl ester, TCR T cell receptor

Journal: Cancer Immunology, Immunotherapy : CII

Article Title: CD45RA − Foxp3 high regulatory T cells have a negative impact on the clinical outcome of head and neck squamous cell carcinoma

doi: 10.1007/s00262-017-2021-z

Figure Lengend Snippet: Frequency and characteristics of Treg subsets in patients with HNSCC and in those with benign tumors. The gating strategies for Treg subsets in the PBMCs of patients with HNSCC or benign tumors. I: CD45RA+Foxp3low, II: CD45RA−Foxp3low, and III: CD45RA−Foxp3high (a). The expression of CTLA-4, CD25, and CCR4 on Treg subsets in a representative patient with HNSCC (b). Mean fluorescence intensities (MFI) are indicated in the upper right quadrant. CFSE dilutions of proliferated CD4+ T cells were assessed after 72 h of TCR stimulation with or without indicated Treg subsets at a 1:1 ratio (c), and the number of proliferated CD4+ T cells after the co-culture are shown (d). The percentage of Foxp3+ cells in CD4+ T cells (e), CD45RA−Foxp3high Tregs in CD4+ T cells (F), CD45RA+Foxp3low Tregs in CD4+ T cells (g) and the ratio of CD45RA−Foxp3high Tregs to CD45RA+Foxp3low Tregs (h) in PBMCs of patients with HNSCC (n = 46) and benign tumors (n = 23) before treatment. The percentage of CD45RA−Foxp3high Tregs and the ratio of CD45RA−Foxp3high Tregs to CD45RA+Foxp3low Tregs were increased according to clinical stage (i). Statistical comparisons were performed using the parametric unpaired t test. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001. n.s. not significant, HNSCC head and neck squamous cell carcinoma, CTLA-4 cytotoxic T-lymphocyte antigen 4, CCR CC chemokine receptor, CFSE carboxyfluorescein diacetate succinimidyl ester, TCR T cell receptor

Article Snippet: Enriched CD3 + T cells were labeled with CellTrace CFSE (carboxyfluorescein diacetate succinimidyl ester) Cell Proliferation Kit (Molecular Probes, USA) according to the manufacturer’s instructions.

Techniques: Expressing, Fluorescence, Co-Culture Assay

Journal: Cell Reports

Article Title: Iterative Single-Cell Analyses Define the Transcriptome of the First Functional Hematopoietic Stem Cells

doi: 10.1016/j.celrep.2020.107627

Figure Lengend Snippet:

Article Snippet: Rat anti-Mouse CD117-BV421 (c-Kit) (clone 2B8) , BD Biosciences , Cat#562609; RRID: AB_11154585.

Techniques: Recombinant, dsDNA Assay, Sample Prep, Software, Selection